Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Exclusion Criteria

• •1. Those who have clinically significant disease or medical history of heart failure, Hepatopathy, Type 1 Diabetes, Diabetic ketoacidosis, Edema, Renal dysfunction, galactose intolerance, glucose-galactose malabsorption. And Those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) during clinical trial.
• •2. Those who have past medical history of gastrointestinal disorder (Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of investigational drug.
• •3. Those who have the test results written below
• •* AST, ALT \> 2 times higher than upper normal level
• •4. Those who exceeding an alcohol consumption criteria(210g/week) within 6 months before the first administration of investigational drug.
• •* Beer 1 glass(250ml, Alcohol contents 5%) = 10g
• •* Soju 1 glass(50ml, Alcohol contents 20%) = 8g
• •* Wine 1 glass(125ml, Alcohol contents 12%) = 12g
• •5. Those who exceeding smoking criteria(20 cigarettes/day) within 6 months before the first administration of investigational drug.
• •6. Those who received investigational durg by participating in other clinical trial within 6 months before the first administration of investigational drug.
• •7. Those who have vital sign written below
• •* systolic blood pressure ≥140 mmHg or \< 90 mmHg
• •* diastolic blood pressure ≥ 90 mmHg or \< 60 mmHg
• •8. Those who have a drug or alcohol abuse history within 1 year before the first administration of investigational drug.
• •9. Those who take barbiturate and related (causing induction or inhibition. of metabolism) drug within 30 days before the first administration of investigational drug.
• •10. Those who received Ethical-the-counter (ETC) drugs or Over-the-counter (OTC) drugs within 10 days before the first administration of investigational drug.
• •11. Those who donated whole blood within 2 months or apheresis within 1 month before the first administration of investigational drug.
• •12. Those who severe acute/chronic medical or mental condition which can increase the safety risk by administration of investigational drug.
• •13. Those who have history of hypersensitivity to active pharmaceutical ingredient or additives.
• •14. Those who are pregnant or breastfeeding.
• •15. Those who can't ingest a high fat diet.
• •16. Those who are deemed inappropriate to participate in clinical trial by investigators.